Search results for " ascites"

showing 9 items of 19 documents

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

2022

Background & Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Methods Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results One hundred PBC cirrhotics were included, 97…

Liver CirrhosisMaleliver decompensationsafetyHepatologyLiver Cirrhosis Biliarydecision curve analysis; efficacy; liver decompensation; safety; total bilirubin; Albumins; Ascites; Bilirubin; Chenodeoxycholic Acid; Humans; Liver Cirrhosis; Male; Liver Cirrhosis BiliaryBiliaryefficacyAscitesBilirubinChenodeoxycholic Acidtotal bilirubindecision curve analysiSettore MED/12AlbuminsHumansdecision curve analysis
researchProduct

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data

2007

Several randomized controlled trials have compared a transjugular intrahepatic portosystemic shunt (TIPS) with large-volume paracentesis in cirrhotic patients with refractory ascites. Although all agree that TIPS reduces the recurrence rate of ascites, survival is controversial. The aim of this study was to compare the effects of TIPS and large-volume paracentesis in cirrhotic patients with refractory ascites by means of meta-analysis of individual patient data from 4 randomized controlled trials.The study population consisted of 305 patients: 149 allocated to TIPS and 156 to paracentesis. Cumulative probabilities of transplant-free survival and of hepatic encephalopathy (HE) were estimated…

Liver CirrhosisMalemedicine.medical_specialtymedicine.medical_treatmentKaplan-Meier EstimateGastroenterologySpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseHepatorenal syndromeRisk FactorsInternal medicineAscitesmedicineParacentesisHumansParacentesisHepatic encephalopathyAgedFirst episodeHepatologymedicine.diagnostic_testbusiness.industrySodiumGastroenterologyAscitesBilirubinPatient dataMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTreatment OutcomeMeta-analysisHepatic EncephalopathyRegression AnalysisFemaleRefractory ascitesPortasystemic Shunt Transjugular Intrahepaticmedicine.symptombusinessTransjugular intrahepatic portosystemic shuntGastroenterology
researchProduct

Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (…

2021

Abstract Portal hypertension and ascites are two crucial events in the natural history of liver cirrhosis, whose appearance marks a downward shift in the prognosis of the disease. Over the years, several international and national societies have issued clinical practice guidelines for the diagnosis and management of portal hypertension and ascites. The present document addresses the needs of an updated guidance on the clinical management of these conditions. Accordingly, the AISF Governing Board appointed a multi-disciplinary committee of experts for drafting an update of the most recent EASL Clinical Practice Guidelines. The aim of this work was to adapt the EASL recommendations to nationa…

Liver CirrhosisPopulationScopusDiseaseEsophageal varicesAscitesHypertension PortalMedicineHumanseducationPortal hypertensioneducation.field_of_studyVariceal bleedingHepatologyEsophageal varicebusiness.industryGastroenterologyAscitesmedicine.diseaseAcute kidney injuryClinical PracticeNatural historyVariceal bleeding.ItalyAcute kidney injury; Ascites; Esophageal varices; Hepatorenal syndrome; Portal hypertension; Variceal bleeding; Ascites; Humans; Hypertension Portal; Italy; Liver CirrhosisHypertensionAscitePortal hypertensionHepatorenal syndromePortalMedical emergencymedicine.symptombusinessResource utilizationHuman
researchProduct

Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF) - more common than assumed? Report of four cases with transient NIHF and a rev…

2012

Abstract Background Lysosomal storage disorders (LSD) are a rare cause of non immunological hydrops fetalis (NIHF) and congenital ascites. The reported incidence is about 1%. The incidence of idiopathic NIHF is estimated to be about 18%. Patients and methods We report four cases with transient hydrops fetalis resulting from LSD and performed a literature review on LSD with NIHF and congenital ascites in combination. Results At present, 12 different LSDs are described to be associated with NIHF or congenital ascites. Most patients had a family history of NIHF, where the preceding sibling had not been examined. A diagnostic approach to the fetus with NIHF due to suspected LSD either in utero …

MalePathologymedicine.medical_specialtyHydrops FetalisNon-immunological hydrops fetalisPharmacology toxicologylcsh:MedicineLysosomal storage diseaseLysosomal storage disordersClinical approachPregnancyHydrops fetalisAscitesLysosomal storage diseaseHumansMedicineGenetics(clinical)Pharmacology (medical)Genetics (clinical)Medicine(all)business.industryResearchIncidence (epidemiology)lcsh:RTransient hydropsGeneral Medicinemedicine.diseaseCongenital ascitesLysosomal Storage DiseasesImmunologyFemalemedicine.symptombusinessOrphanet Journal of Rare Diseases
researchProduct

Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff’s base to overcome MDR in cancer

2011

Abstract Multidrug resistance (MDR) in cancer, a major obstacle to successful application of cancer chemotherapy, is often characterized by over-expression of multidrug resistance-related proteins such as MRP1, P-gp or elevated glutathione (GSH) level. Efflux of drugs by functional P-gp, MRP1 and elevated GSH level can confer resistance to apoptosis induced by a range of different stimuli. Therefore, it is necessary to develop new cell death inducers with relatively lower toxicity toward non-malignant cells that can overcome MDR by induction of apoptotic or non-apoptotic cell death pathways. Herein we report the synthesis and spectroscopic characterization of a GSH depleting, redox active S…

Programmed cell deathMagnetic Resonance SpectroscopyNecrosisApoptosisMitochondrionBiologymedicine.disease_causeBiochemistryEhrlich ascites carcinomaMiceNecrosisCell Line TumorNeoplasmsSpectroscopy Fourier Transform InfraredmedicineAnimalsCytotoxic T cellCytotoxicitySchiff BasesCalpainCaspase 3General MedicineFlow CytometryGlutathioneMitochondriaBiochemistryDrug Resistance NeoplasmApoptosisCancer researchCalciumSpectrophotometry Ultravioletmedicine.symptomReactive Oxygen SpeciesOxidative stressBiochimie
researchProduct

Pathophysiological Aspects of Glucose Uptake by the Tumor Tissue under Various Conditions of Oxygen and Glucose Supply

1976

Earlier examinations of the glucose uptake in neoplastic tissue by isolated DS- Carcinosarcoma implanted into the rat kidney had the results as follows (VAUPEL, 1974): 1. An increase of the tumor mass from 3 to 13 g wet weight caused an exponential decrease of the glucose consumption by the tumor tissue from 44.4 to 6.7/umoles per 100 g/min; very young tumors of 3 – 4 g bad uptake rates from 27.8 to 44.4/umoles/100 g/min. 2. Simultaneous measurements of the mean actual glucose concentrations in the tumor tissue showed that in the very young tumors the concentration still ranged from 1.75 to 2.25/umoles/g wet weight, whereas those in old tumors drop as low as 0 to 0.17/umoles/g.

medicine.medical_specialtyChemistryGlucose uptakechemistry.chemical_elementCarbohydrate metabolismmedicine.diseaseOxygenTumor tissuePathophysiologyEhrlich ascites carcinomaEndocrinologyInternal medicineCarcinosarcomamedicineGlycolysis
researchProduct

Intavenous high dose furosemide plus small volume of hypertonic saline solutions (HSS) versus seriated paracentesis in treatment of refractory ascite…

2008

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrySmall volumeFurosemideHypertonic salineSurgeryAnesthesiaInternal MedicineParacentesismedicineRefractory ascitesbusinessmedicine.drug
researchProduct

Chylous ascites after lymphadenectomy for gynecological malignancies

2016

Background and Objectives Chylous ascites, an accumulation of milky-white lymph fluid in the peritoneal cavity, is a rare complication following retroperitoneal lymphadenectomy. This study evaluated the appearance and management of chylous ascites following lymphadenectomy for gynecological malignancies. Methods A total of 931 patients who underwent lymphadenectomy for gynecological malignancies at Erlangen University Hospital between 2002 and 2013 were reviewed retrospectively. Results Chylous ascites occurred postoperatively in 28 of the 931 patients (3.0%). All patients with chylous ascites had undergone combined systematic para-aortic and pelvic lymphadenectomy (SAPL). Patients with chy…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentRetrospective cohort studyGeneral Medicinemedicine.diseaseSurgery03 medical and health sciencesPeritoneal cavity0302 clinical medicinemedicine.anatomical_structureOncology030220 oncology & carcinogenesisChylous ascitesCarcinomamedicine030211 gastroenterology & hepatologySurgeryLymphadenectomyLymphComplicationbusinessLaparoscopyJournal of Surgical Oncology
researchProduct